Ask about this productRelated genes to: CD80 antibody
- Gene:
- CD80 NIH gene
- Name:
- CD80 molecule
- Previous symbol:
- CD28LG, CD28LG1
- Synonyms:
- B7.1, B7-1
- Chromosome:
- 3q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-14
- Date modifiied:
- 2016-10-05
Related products to: CD80 antibody
Related articles to: CD80 antibody
- Mesenchymal stromal cells (MSCs) have shown enhanced therapeutic efficacy by cytokine pre-activation or licensing. Previous research has shown subconjunctival administration of low-dose allogeneic MSCs can significantly promote an anti-inflammatory phenotype. We report the effects of pro-inflammatory TNF-α/IL-1β MSC licensing, evaluating therapeutic potency in vitro and in a preclinical model of corneal alkali chemical burn. - Source: PubMed
Publication date: 2026/05/16
Canning AoifeDonohoe EllenJohnston ÉannaLynch KevinMoosavizadeh SeyedmohammadWang JieminLeahy MartinTreacy OliverRyan Aideen ERitter Thomas - The immunosuppressive bone marrow microenvironment (BMM) and cytokine dysregulation remain major barriers to curing multiple myeloma (MM). Despite the promise of B-cell maturation antigen (BCMA)-targeted therapies, their clinical utility is often limited by antigen escape and insufficient immune activation. Here, we developed DB Exo, a cell-free therapeutic platform utilizing allogeneic dendritic cell-derived exosomes engineered to surface display BCMA. Mechanistically, DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, thereby effectively disrupting NF-κB pro-survival signaling in MM cells. Concurrently, DB Exo retain inherited costimulatory molecules (CD80, CD86, and MHC-II) to trigger strong host immune activation, expanding CD8 T cells and enhancing the secretion of cytotoxic effector molecules. In an orthotopic murine model, DB Exo suppress tumor burden by ∼72% and remodel the BMM by increasing cytotoxic T-lymphocyte infiltration and elevating serum IFN-γ and Granzyme B levels. The robust antitumor efficacy was further validated in a subcutaneous model, with DB Exo achieving a ∼75% reduction in tumor weight. Our findings establish DB Exo as a potent bi-functional exosome platform that integrates targeted cytokine blockade with in situ immune activation, offering a promising cell-free strategy for MM treatment. - Source: PubMed
Publication date: 2026/05/15
Zeng YuqingHe ChaoHe ZhibinChen HongboCheng FangZheng Yongjiang - Periodontitis and apical periodontitis (AP) are characterized by biofilm-driven, immune-mediated bone destruction. Macrophages orchestrate the immune imbalance, where the M1/M2 polarization axis is critical for tissue homeostasis. - Source: PubMed
Publication date: 2026/05/14
González-Quintanilla DavidCastro-Saavedra SebastiánBordagaray María JoséLucero-Mora JoaquínVernal RolandoPaula-Lima AndreaFernández AlejandraHernández Marcela - Melanoma is a highly aggressive malignancy characterized by limited immunogenicity and pronounced immune evasion, which represent significant obstacles to effective therapeutic intervention. Building on our previously developed multifunctional PDA-Ce6-R837 nanoparticles (NPs), which have demonstrated favorable antitumor efficacy in squamous cell carcinoma (SCC) models, the present study shifts focus toward elucidating their underlying photo-immunological mechanisms in melanoma cells. Here, we investigate their antitumor and immunoregulatory effects in melanoma cell models. studies demonstrated the efficient internalization of PDA-Ce6-R837 NPs by SK-Mel-28 and A375 cells, which was accompanied by pronounced photothermal and photodynamic responses. Functional assays revealed that this treatment markedly suppressed cell migration and invasion and, under dual-wavelength laser irradiation, significantly induced apoptosis while promoting key hallmarks of immunogenic cell death (ICD), including the translocation of calreticulin (CRT) and the extracellular release of adenosine triphosphate (ATP) and high-mobility group box 1 (HMGB1). In coculture systems, treatment with R837 alone promoted the maturation of bone marrow-derived dendritic cells (BMDCs), whereas laser activation of PDA-Ce6-R837 NPs enhanced BMDC maturation, as evidenced by further upregulation of CD80/CD86 expression and increased IL-12p70 production. Collectively, these findings demonstrate that PDA-Ce6-R837 NPs combine direct cytotoxic effects with immune stimulation in melanoma phototherapy, offering experimental evidence to support the development of phototherapy-based immunotherapeutic strategies for melanoma. - Source: PubMed
Publication date: 2026/05/12
Wang JianvLiu ChenxiZhang XiaoyanXie YaoZhang XueyuWang TingtingWang Lin - Immune checkpoint inhibitors have transformed cancer therapy, yet many patients fail to respond, underscoring the need for complementary strategies. Personalized neoantigen cancer vaccines (NCVs), which stimulate highly specific T-cell responses against tumor-specific mutations, are a promising approach now advancing in clinical development. - Source: PubMed
Publication date: 2026/05/13
Tonini ClaudiaBianchi AndreaEsposito MauroEsposito IlariaGiacomelli TizianoYoung EmilyLanckriet HeikkiWhiffen ZoePavlickova MilenaEntiriwaa DeborahPrincipato EugeniaRoscilli GiuseppePiconese SilviaLione LuciaSalvatori ErikaPinto EleonoraCiliberto GennaroAurisicchio LuigiWalker AmyPalombo Fabio